Literature DB >> 10853817

Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake.

M J Reinhardt1, F D Jüngling, T M Krause, S Braune.   

Abstract

Primary dysfunction of the autonomic nervous system can be observed in patients with Parkinson's disease and those with multiple system atrophy. However, the fate of the two diseases differs considerably and leads to different strategies for patient management. Differentiation of the two diseases currently requires a combination of several clinical and electrophysiological tests. First studies of myocardial innervation using iodine-123 metaiodobenzylguanidine (MIBG) indicated a possible role of scintigraphy for this purpose. An increase in the pulmonary uptake of 123I-MIBG has been reported in secondary dysautonomias. Whether sympathetic innervation of the lung is affected in primary dysautonomias is currently unknown. Therefore, cardiac and pulmonary uptake of 123I-MIBG was studied in 21 patients with Parkinson's disease, 7 patients with multiple system atrophy and 13 age- and sex-matched controls. Thoracic images were obtained in the anterior view 4 h after intravenous injection of 185 MBq 123I-MIBG, at which time the maximum neuronal uptake is reached. All patients with Parkinson's disease had significantly lower cardiac uptake of 123I-MIBG than patients with multiple system atrophy and controls. Sympathetic innervation of the lung was not affected in either disease. It is concluded that scintigraphy with 123I-MIBG appears to be a useful tool for differentiation between Parkinson's disease and multiple system atrophy early after onset of autonomic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10853817     DOI: 10.1007/s002590050548

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  19 in total

Review 1.  Cardiac sympathetic neuroimaging to distinguish multiple system atrophy from Parkinson disease.

Authors:  D S Goldstein
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

Review 2.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

Review 3.  Cardiac receptor physiology and its application to clinical imaging: present and future.

Authors:  H Tseng; J M Link; J R Stratton; J H Caldwell
Journal:  J Nucl Cardiol       Date:  2001 May-Jun       Impact factor: 5.952

Review 4.  Imaging the Autonomic Nervous System in Parkinson's Disease.

Authors:  Karoline Knudsen; Per Borghammer
Journal:  Curr Neurol Neurosci Rep       Date:  2018-09-19       Impact factor: 5.081

Review 5.  Functional imaging with positron emission tomography in multiple system atrophy.

Authors:  S Gilman
Journal:  J Neural Transm (Vienna)       Date:  2005-08-05       Impact factor: 3.575

Review 6.  The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes.

Authors:  S Braune
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

Review 7.  Dysautonomia in Parkinson disease.

Authors:  David S Goldstein
Journal:  Compr Physiol       Date:  2014-04       Impact factor: 9.090

Review 8.  MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis.

Authors:  Giorgio Treglia; Ernesto Cason; Antonella Stefanelli; Fabrizio Cocciolillo; Daniela Di Giuda; Giorgio Fagioli; Alessandro Giordano
Journal:  Clin Auton Res       Date:  2011-07-27       Impact factor: 4.435

9.  Feasibility of 2-deoxy-2-[18F]fluoro-D-glucose- A85380-PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo.

Authors:  Jan Bucerius; Alexius Y Joe; Jörn Schmaljohann; Daniela Gündisch; Martina Minnerop; Hans-Jürgen Biersack; Ullrich Wüllner; Michael J Reinhardt
Journal:  Clin Res Cardiol       Date:  2006-01-19       Impact factor: 5.460

10.  Orthostatic hypotension as an early finding in Parkinson's disease.

Authors:  David S Goldstein
Journal:  Clin Auton Res       Date:  2006-02       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.